Cancer chemoprevention

Current Opinion in Gastroenterology

Volumn 15, Issue 1, 1999, Pages 9-15

  Brenner, Dean E ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

CHEMOPROPHYLAXIS; COLORECTAL CANCER; NUTRIENT; NUTRITION; REVIEW;

EID: 0033037736     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-199901000-00003     Document Type: Review

References (39)

1. 1 Gann PH, Manson JE, Glynn RJ, Buring JE, Hennekens CH: Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 1993, 85:1220-1224.
2. 2 Sturmer T, Glyn R, Lee I, Manson Je, Buring J, Hennekins C: Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians Health Study. Ann Intern Med 1998, 128:713-720. In this large, prospective clinical trial of aspirin and beta-carotene as preventives for cardiovascular disease, aspirin after 7 years of treatment did not reduce the risk of colorectal cancer. This trial contradicts many retrospective epidemiologic studies that suggest long-term intake of aspirin reduces the risk of colorectal cancer.
3. 3 Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, et al.: Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995, 333:609-614.
4. 2 are reduced by sulindac.
5. 5 Winde G, Schmid K, Brandt B, Muller O, Osswald H: Clinical and genomic influence of sulindac and rectal mucosa in familial adenomatous polyposis. Dis Colon Rectum 1997, 40:1156-1168. A prospective, variable dosing trial of sulindac flattens polyps in patients with familial adenomatous polyposis. Tissue surrogates associated with cellular proliferation and apoptotic control correlate with flattening of polyps. Sulindac reduces the rectal mucosa prostaglandins detected using mass spectrometry.
6. 6 Ruffin M, Krishnan K, Rock C, Normolle D, Vaerten M, Peters-Golden M, et al: Suppression of human colorectal mucosal prostaglandins: determining the lowest effective aspirin dose. J Natl Cancer Inst 1997, 89:1152-1160. Low doses (81 mg once daily) of aspirin inhibit colorectal mucosal prostaglandin production.
7. 7 Matsuhashi N, Nakajima A, Fukushima Y, Yazaki Y, Oka T: Effects of sulindac on sporadic colorectal adenomatous polyps. Gut 1997, 40:344-349. Sulindac given over 4 months reduces the size and numbers of sporadic polyps in human subjects.
8. 8 Winde G, Gumbinger HG, Osswald H, Kemper F, Bunte H: The NSAID sulindac reverses rectal adenomas in colectomized patients with familial adenomatous polyposis: clinical results of a dose-finding study on rectal sulindac administration. Int J Colorectal Dis 1993, 8:13-17.
9. 9 Giardiello FM, Hamilton SR, Krush AJ, Piantadosis S, Hylind LM, Celano P, et al.: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993, 328:1313-1316.
10. 10 Mahmoud N, Boolbol S, Dannenberg A, Mestre J, Bilinski R, Martucci C, et al.: The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis. Carcinogenesis 1998, 19:87-91.
11. 11 Chiu C, McEntee M, Whelan J: Sulindac causes rapid regression of preexisting tumors in Min/+ mice independent of prostaglandin biosynthesis. Cancer Res 1997, 57:4267-4271.
12. 12 Piazza G, Alberts D, Hixon L, Paranka N, Li H, Finn T, et al: Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 1997, 57:2909-2915. Inhibition of COX is not necessary to inhibit carcinogen-induced polyps and tumors in a standard chemical carcinogenesis model.
13. 13 Piazza G, Rahm A, Finn T, Fryer B, Li H, Souman A, et al: Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res 1997, 57:2452-2459.
14. 14 Samaha H, Kelloff G, Steele V, Rao CV, Reddy B: Modulation of apoptosis by sulindac, curcumin, phenyethyl-3-methylcaffeate, and 6-phenylhexyl isothioscyanate: apoptotic index as a biomarker in colon cancer chemoprevention and promotion. Cancer Res 1997, 57:1301-1305. Many chemopreventive agents induce apoptosis.
15. 15 Hughes-Fulford M, Boman B: Growth regulation of Gardner's syndrome colorectal cells by NSAIDs. Adv Exp Biol Med 1997, 407:433-441.
16. 16 Wechter W, Kantoci K, Murray E, Quiggle D, Leipold D, Gibson K, McCracken J: R-Flurbiprofen chemoprevention and treatment of intestinal adenomas in the APCMin/+ mouse model: implications for prophylaxis and treatment of colon cancer. Cancer Res 1997, 57:4316-4324. R-Flurbiprofen does not inhibit COX activity yet reduces intestinal adenomas in a murine APC genetic mutation model. The rodent converts R-flurbiprofen to L-flurbiprofen, a COX inhibitor, in small amounts. The concentration of L-flurbiprofen produced in the mouse is insufficient to account for the reduction in intestinal adenomas.
17. 17 Barnes C, Cameron I, Hardman W, Lee M: Non-steroidal anti-inflammatory drug effect on crypt cell proliferation and apoptosis during initiation of rat colon carcinogenesis. Br J Cancer 1998, 77:573-580.
18. 18 Kawamori T, Rao C, Seibert K, Reddy B: Chemopreventive effect of celecoxib, a specific cyclooxygenase-2 inhibitor on colon carcinogenesis. Cancer Res 1998, 58:409-412. A selective COX-2 inhibitor has exceptional anticarcinogenesis activity in a standard rat chemical carcinogenesis model.
19. 19 Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, et al.: Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996, 87:803-809.
20. 20 Kalgutkar A, Crews B, Rowlinson S, Garner C, Seibert K, Marnett L: Aspirin-tike molecules that covalently inactivate cyclooxygenase-2. Science 1998, 280:1268-1270. Chemical modification of the aspirin molecule can produce potent selective COX inhibitors.
21. 21 Hofstad B, Almendingen K, Vatn M, Andersen S, Owen R, Larsen S, Osnes M: Growth and recurrence of colorectal polyps: a double-blind 3-year interventiion with calcium and antioxidants. Digestion 1998, 59:148-156. A combination of calcium, beta-carotene, selenium, and vitamin C did not inhibit the growth rate or recurrence of sporadic polyps over a 3-year observation period.
22. 22 White E, Shanon J, Patterson R: Relationship between vitamin and calcium supplement use and colon cancer. Cancer Epidemiol Biomarkers Prev 1997, 6:769-774.
23. 23 Greenberg ER, Baron JA, Tosteson TD, Freeman DH Jr, Beck GJ, Bond JH, et al.: A clinical trial of antioxidant vitamins to prevent colorectal adenoma: Poly Prevention Study Group. N Engl J Med 1994, 331:141-147.
24. 24 Hyman J, Baron J, Dain B, Sandler R, Haile R, Mandel J, et al: Dietary and supplemental calcium and the recurrence of colorectal adenomas. Cancer Epidemiol Biomarkers Prev 1998, 7:291-295. A retrospective analysis of the antioxidant polyp prevention trial from Dartmouth found that high calcium intake in the diet (≥1,044 mg/d) was associated with reduced relative risk of polyp recurrence.
25. 25 Konings E, Greenberg E: Antioxidant supplements and colorectal cancer. Nutrition 1998, 14:245-247.
26. 26 MacLennan R, Macrae F, Bain C, Battistutta D, Chapuis P, Gratten H, et al: Randomized trial of intake of fat, fiber, and beta carotene to prevent colorectal adenomas: The Australian Polyp Prevention Project. J Natl Cancer Inst 1995, 87:1760-1766.
27. 27 Bostick R, Fosdick L, Grandits G, Lillemoe T, Wood J, Grambasch P, et al: Colorectal epithelial cell proliferative kinetics and risk factors for colon cancer in sporadic adenoma patients. Cancer Epidemiol Biomarkers Prev 1998, 6:1011-1019. High fruit consumption, daily vitamin supplement intake, and low sucrose intake are associated with reduced cellular labeling index in rectal mucosa obtained from human subjects with sporadic adenomatous polyps.
28. 28 Ingles S, Bird C, Shinkany J, Frankl H, Lee E, Haile R: Plasma tocopherol and prevalence of colorectal adenocarcinomas in a multiethnic population. Cancer Res 1998, 58:661-666. Polymorphism in lipid metabolism as reflected by the fractions of human lipid profiles predict bioavailability of tocopherol. Food frequency data are insufficient to predict bioavailability of an important micronutrient. Diet-cancer relationships are influenced in individual variations in key plasma binding molecules that transport dietary micronutrients from absorption sites to metabolic and cellular function sites.
29. 29 Rao CV, Rivenson A, Simi B, Reddy BS: Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound. Cancer Res 1995, 55:259-266.
30. 30 Huang MT, Lou YR, Ma W, Newmark HL, Reuhl KR, Conney AH: Inhibitory effects of dietary curcumin on forestomach, duodenal, and colon carcinogenesis in mice. Cancer Res 1994, 54:5841-5847.
31. 31 Hanif R, Qiao L, Shift S, Rigas B: Curcumin, a natural plant phenolic food additive inhibits cell proliferation and induces cell cycle changes in colon adenocarcinoma cell lines by a prostaglandin-independent pathway. J Lab Clin Med 1997, 130:576-584.
32. 32 Tao L, Li K, Pereira M: Chemopreventive agents-induced regression of azoxymethane-induced aberrant crypt foci with the recovery of hexosaminidase activity. Carcinogenesis 1997, 18:1415-1419.
33. 33 Kim J, Araki S, Kim D, Park C, Takasuka N, Baba-Toriyama H, et al: Chemopreventive effects of carotenoids and curcumins on mouse colon carcinogenesis after 1,2-demethylhydrazine initiation. Carcinogenesis 1998, 19:81-85.
34. 34 Clark LC, Combs GF Jr, Turnbull BW, Slate EH, Chalker DK, Chow J, et al.: Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996, 276:1957-1963.
35. 35 Reddy B, Rivenson A, El-Bayoumy K, Upadhyaya P, Pittman B, Rao C: Chemoprevention of colon cancer by organoselenium compounds and impact of high-and low-fat diets. J Natl Cancer Inst 1997, 89:506-512. Two organoselenium molecules are potent inhibitors of colonic carcinogenesis in both low-fat and high-fat diets but are particularly active in animals fed a low-fat diet.
36. 36 Reddy B, Xan C, Samaha H, Lubet R, Steele V, Kelloff G, Rao C: Chemoprevention of colon carcinogenesis by dietary perillyl alcohol. Cancer Res 1997, 57:420-425.
37. 37 Tanaka T, Kawabata K, Kakumoto M, Hara A, Murakami A, Kuki W, et al: Citrus auraptene exerts dose-dependent chemopreventive activity in rat large bowel tumorigenesis: the inhibition correlates with suppression of cell proliferation and lipid peroxidation and with induction of Phase II drug metabolizing enzymes. Cancer Res 1998, 58:2550-2556.
38. 38 Tanaka T, Kawabata K, Kakumoto M, Makita H, Matsunaga K, Mori H, et al: Chemoprevention of azoxymethane-induced rat colon carcinogenesis by a xanthine oxidase inhibitor, 1′-acetoxychavicol acetate. Jpn J Cancer Res 1997, 88:821-830.
39. 39 Tanaka T, Makita H, Kawabata K, Mori H, Kakumoto M, Satoh K, et al: Chemoprevention of azoxymethane-induced rat colon carcinogenesis by the naturally occurring flavonoids, diosmin and hesperidin. Carcinogenesis 1997, 18:957-965.